Abstract | BACKGROUND: METHODS: RESULTS: TP staining intensities in both the invasive and in situ components in patients with lobular and ductal carcinomas were reported. Higher levels of TP in the invasive component were expressed in ER-negative tumors when compared with ER-positive tumors (P<0.05). The ER-positive group expressing lower levels of TP had a median time to progression of 13 months compared with the ER-negative group expressing higher levels of TP which had a median time to progression of 7.5 months (P=0.14). CONCLUSION: Patients with ER-positive tumors expressing lower levels of TP exhibit a longer time to progression when compared with patients with ER-negative tumors. Consequently, tumor TP expression does not seem to predict the outcome of capecitabine-based chemotherapy.
|
Authors | Anna Lisa Tedeschi, Zohreh Eslami, Evgenia Garoufalis, Ramy R Saleh, Atilla Omeroglu, Gulbeyaz Altinel, Maria Ait-Tihyaty, Bertrand Jean-Claude, Catalin Mihalcioiu |
Journal | OncoTargets and therapy
(Onco Targets Ther)
Vol. 8
Pg. 911-9
( 2015)
ISSN: 1178-6930 [Print] New Zealand |
PMID | 25960662
(Publication Type: Journal Article)
|